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ABSTRACT 
Exploring structural modifications and biomarkers to optimize and expand the E-DNA 
scaffold sensor for applications in point of care serology  
By 
Ava Shruti Kartik Greenwood 
 
Serology provides comprehensive information about infection, disease progression, 
and immune history. Current technologies utilized for serological diagnosis exist in one of 
the following modalities: 1) rapid, qualitative and easy to use in complex clinical samples, 
but limited to a single diagnostic biomolecule, 2) cutting edge and quantitative but 
computationally expensive and unable to perform well in complex clinical samples, or 3) 
quantitative, robust and easily multiplexed using complex samples while being time and 
equipment intensive. To bridge the gap between rapid and qualitative and time/equipment 
intensive and quantitative, our group has developed electrochemical DNA (E-DNA) scaffold 
sensors to quantitively detect diagnostic antibodies in a rapid, single step, wash free, 
electrochemical system. The overreaching goal is to develop an inexpensive, multiplexed E-
DNA scaffold sensor to detect multiple diagnostic antibodies at the point of care in less than 
15 minutes – which will improve patient outcomes and reduce the number of patients lost to 
follow-up.  
The work presented here focuses on improving the analytical and clinical 
performance of the E-DNA scaffold sensors, in addition to expanding the platform to 
diagnose multiple sexually transmitted infections. Compared to the scaffold sensor structure 
in previously published literature, various modifications of the scaffold sensor flexibility and 
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utilization of a bivalent epitope probe did not improve the overall current, signal gain, or 
limit of detection of the E-DNA scaffold sensor. Attempts at expanding the E-DNA scaffold 
sensor to detect anti-gp41 diagnostic antibody in clinical samples resulted in a successful 
sensor that approaches the sensitivity and selectivity necessary clinical utilization, however 
incorporation of two linear epitopes of herpes simplex virus type 2 and hepatitis C were 
unsuccessful with the linear epitopes employed. Difficulties in expanding the diagnostic 
biomarkers utilized in this platform stem from issues incorporating linear immunodominant 
epitopes, which demonstrate positive and negative predictive value when challenged with 
human sera using gold standard techniques yet demonstrate no significant signal change 
when incorporated into the E-DNA scaffold. 
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Chapter 1. Introduction 
1.1 Serology at the point of care 
Blood and blood products, such as serum and plasma, contain molecular 
biomarkers that can provide us with a unique and unparalleled view of metabolism, 
infection, auto-immune disease, oncology, and a patient’s response to treatment1–3. Thus 
motivated, serology is the study of the protein, cellular and metabolic components of the 
blood to gain meaningful insight into an individual’s current health. Use of serology 
typically occurs during a patient’s visit to a physician for diagnostic or wellness purposes, 
where in blood is drawn and relevant studies are performed to provide the medical 
practitioner with an in depth look into the biology behind a patient’s symptoms.  
 The 21st century is rapidly becoming characterized by the ease and speed with which 
we can accomplish most tasks, and yet obtaining meaningful, actionable health related 
results is still a slow and cumbersome process. In the typical primary care provider-
patient interaction, one must make an appointment to discuss their symptoms and 
undergo a physical exam, where the provider listens to a medical history of the ailment 
and orders a number of serological tests for diagnostic purposes. Unless one is in a 
hospital (such as emergency department), patients are typically referred to an off-site, 
centralized facility to have their blood taken by a phlebotomist4. There, the sample is 
either tested by a technician with specialized training and equipment or sent to a 
centralized facility that performs these tests regularly. In addition to the time required to 
draw blood and transport it to a facility appropriately equipped to carry out the diagnostic 
tests of interest, most serological diagnostic tests are likewise slow as they are multistep 
and require long incubation times3,5–7. If we evaluate this timeline, we see that the lag 
2 
 
between a patient-physician interaction and the time the physician receives actionable 
diagnostic information ranges from hours (if testing is performed in a hospital) to days (if 
the sample needs to be collected separately and processed at a separate, centralized 
facility)8,9. Clearly there is room for improvement in the current, laboratory-centric 
approach to the measurement of molecular markers. 
Given that a typical patient-physician interaction lasts approximately 15 
minutes10, it would be useful to develop serological tests that can provide significant 
diagnostic information within this timeframe, such that health care providers can make 
informed decisions about patient care in a timely manner: at the “point of care.” To aid 
(and focus) efforts to develop such technologies the World Health Organization has come 
up with a set of guidelines, ASSURED. The acronym relates the following conditions for 
the development of point of care diagnostic tests: affordable, sensitive, specific, user-
friendly, robust and rapid, equipment free, deliverable to those who need them2. The 
development and subsequent use of point of care diagnostic testing has many benefits 
both in the developed and developing world: namely, it will increase the speed and 
frequency of detection and diagnosis, thus allowing providers to take appropriate steps to 
treat an identified ailment/disease in a single visit; reduce the number of patients who are 
lost to follow up; allow for enhanced screening and treatment in remote clinics and areas 
where routine healthcare is interrupted; and provide a means for epidemiological 
surveillance of disease in near real-time; all of which will lower the transmission of 
disease and contribute to improved patient outcomes. 
Perhaps the most widespread and informative diagnostic biomarkers in use are 
antibodies. These Y-shaped proteins (for the immunoglobulin G class), produced by the 
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immune system in response to pathogens such as viruses, bacteria and fungi11 or, 
sometimes, the body itself, consist of a constant region and a variable region. The 
variable region, which is located at the ends of the two arms of the Y, non-covalently 
binds to antibody’s target molecule, called the antigen. The region on the antigen the 
antibody binds to can either be a contiguous amino acid sequence, called a linear epitope, 
or based on amino acid proximity in the native state of the antigen, called a 
conformational epitope. As the culmination of millions of years of evolution perfecting 
non-covalent binding events, antigen-antibody interactions are highly specific and highly 
selective12.  
1.2 Current point of care diagnostic techniques for detecting antibodies 
While the appeal of point of care diagnostic testing has driven decades of research 
to achieve this end, there are currently only two types of tests that are being employed in 
the field: lateral flow immunoassays (LIAs) and agglutination assays. Both are utilized to 
detect diagnostic antigens or antibodies against a specific biomolecule as a means of 
diagnosing viral, bacterial, or fungal pathogens3,13,14. 
LIAs are small easily utilized serological devices, otherwise known as “dip-
sticks,” the most mainstream of which is the at home pregnancy test. A typical LIA 
utilizes a protein adsorption resistant membrane, such as cellulose, that utilizes capillary 
action to diffuse a serological sample of interest, such as blood or serum, through the 
membrane to a “test line” and a “control line”15,16. The conjugation pad, where the target 
biomolecule is bound by a reporter, typically utilizes a nanoparticle labeled biomolecule 
conjugate, with either a metal/carbon-based nanoparticle that elicits an observable color 
change or luminescent nanoparticles that can be interpreted optically13. The test line 
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consists of a primary biomolecule against the target analyte, whereas the control typically 
consists of a secondary biomolecule that recognizes a universally present target, typically 
an antibody against the constant region of human immunoglobulin G (IgG)3,13,15,16 
(Figure 1). As the sample diffuses through the conjugation pad, serological targets 
against the test (if present) and the control specifically and selectively bind with the 
labeled conjugate biomolecule. As they travel down the length of the LIA, they are then 
captured by the primary and secondary biomolecules. If the target molecule is present in 
a high enough concentration an observable signal indicative of that disease will appear 
within the few minutes afforded for a point of care device.  
 
Figure 1: Schematic of lateral flow immunoassay. Small volumes (~20 uL) of unprocessed clinical samples 
(e.g. serum or blood) are added to the sample pad. Through capillary action the sample flows towards the 
absorption pad. The control biomarker and the target biomarker of interest, if present, conjugates with the 
biomolecule conjugate in the conjugation pad. They are then captured by the capture biomarkers on either 
the test or control lines. In high enough concentrations of the target biomolecule, accumulation of the 
labeled biomolecule conjugate yeilds a visible color change. Figure taken from Bahadir et al. 2016. 
 
Agglutination assays utilize the ability of antibodies to clump together cells or 
particles in the presence of a target antigen. While agglutination occurs naturally in the 
body (hemagglutination), diagnostic tests utilizing this phenomenon have been developed 
by attaching diagnostic antibodies to latex beads14. In the presence of the target pathogen, 
which expresses the antigen of interest, the antibodies on multiple latex beads will bind to 
5 
 
a single pathogen, resulting in the formation of visually observable aggregate14 (Figure 
2). However, the same limitations present for the LIA also exist here—results depend on 
a visual interpretation.  
 
Figure 2: Agglutination assay in action. Latex beads conjugated with specific diagnostic antibodies 
recognize the pathogen of interest through highly specific antibody-antigen interactions. In the presence of 
multiple pathogens, the multiple latex bead antibody and pathogen antigen interactions cause visible 
clumping in the clinical sample. Figure taken from Ortega-Vinuesa et al., 2001.  
 
In controlled environments, both LIAs and agglutination assays often achieve 
sensitivity and selectivity over 95%, but when utilized at the point of care performance 
diminishes significantly13,15,17. Further problems arise when these tests are utilized in the 
field, namely that false negatives or positives can be diagnosed due to method of reading 
the test—using the human eye. While easy to utilize and rapid, there are two inherent 
factors that affect the scope and implementation of these point of care diagnostic devices: 
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the inability to detect multiple targets in a single complex sample, and the necessity of a 
high antibody titer coupled with the absence of quantitative biomarker information.  
Commercially available LIAs are limited to the detection of one specific biomolecule, 
and therefore, are only used to detect one disease. Limitations of the current LIA design, 
which make them able to only detect a single target biomolecule, stem from interference 
of different target biomolecules and difficulty tuning the spatial separation of test strips. 
These factors can only be resolved by larger sample volumes and longer test strips, which 
means longer wait times for diagnosis. Furthermore, introducing multiplexing to a LIA 
comes at the expense of simplicity and operability by untrained personnel3. Similarly, 
agglutination assays can only detect one target because complex samples contain diffuse 
pathogens and biomarkers, and one would not be able to determine if aggregation is the 
result of one or more targets. Attempts at creating a multiplexed agglutination test 
requires a complex microfluidic system, automated addition of patient samples, and 
computerized interpretation of array results18. Similar to LIA, this multiplexable 
agglutination assay comes at the cost of large patient sample volumes and diminishes the 
ease of use for personnel without specialized training and equipment. As of 2019, there is 
one commercially available LIA  and no agglutination assays that meet the ASSURED 
criteria set by the WHO that detect multiple biomarkers and/or diseases6,19,20. 
Current commercially available point of care devices rely on a visually interpreted 
signal output in response to a relatively high diagnostic antibody concentration. The 
limits of detection for LIAs and agglutination assays are within the single nanomolar 
regime when performed in buffer in a laboratory environment3,13, however when 
challenged with complex samples in the field they typically miss seroconversion of a 
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patient during the initial stages of infection. This is due to the necessity of a high 
antibody titer, which is the concentration of antibody that the body has generated against 
a specific target, relative to all other antibodies present. Quantifying the intensity of a 
color on the test line on a LIA or the size of the clump as a result of agglutination to 
determine target biomolecule concentration is inexact, especially when interpreting these 
results using the human eye. As a result, neither diagnostic platforms are able to provide 
quantifiable biomarker information. As a result of these limitations, these assays are 
typically utilized at the point of care for initial diagnosis, wherein a second sample is sent 
off for more comprehensive and robust testing in a laboratory19. 
1.3 Other techniques in development for point of care antibody diagnostics 
Another method that is currently in development for point of care antibody 
diagnostics is the wash-free fluorescence polarization immunoassay (FPA). Polarized 
light is used to excite a fluorescent dye or label that is attached to a target molecule, 
causing a change in photon emission relative to the plane of polarization as a function of 
complex size21. A typical FPA utilizes a fluorescent tag covalently linked to an antigen, 
with a known fluorescence polarization that is directly dependent on the effective 
molecular size of the fluorophore-antigen conjugate. Upon binding of the target 
diagnostic antibody to the fluorophore-antigen conjugate, the effective molecular size 
drastically increases, resulting in a higher polarization of the emitted photon22. 
The results of the FPA are then compared to those of a standard curve of 
fluorescence polarization versus target antibody concentration, which yields a 
quantitative result as long as antibody concentration is within the limit of detection22. 
Unfortunately, the FPA typically results in a small observable change in signal, as low as 
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15%, with background fluorescence polarization from non-specific adsorption typically 
around 10%, indicating a net 5% signal change to inform for diagnosis. Because of this, 
considerable signal averaging, background subtraction, and large sample volume 
requirements limit the applications of this technique. Furthermore, this process is not 
easily multiplexed and requires the use of specialized equipment and has only been 
successfully utilized in well-equipped facilities23. 
 
 
Figure 3: Schematic of the principle behind fluorescence polarization anisotropy. In the absence of target, the 
fluorophore-antigen pair emits a photon at a known angle relative to the angle excitation of plane polarized 
light. Binding of the antibody to the fluorophore-antigen pair drastically increases the effective size of the 
complex, and thus changes the angle of photon emission to the same polarized light. Figure above was taken 
from Smith et al. 2008. 
 
Motivated by the need for improved point of care serological methods, a wide range 
of new molecular biosensors and techniques have emerged to fill this gap. Because most 
antibody-antigen binding events do not undergo a conformational change, they do not 
produce any easily measurable or observable signal22,23. As such, methods have been 
developed that monitor antibody-antigen binding via associated changes in adsorbed 
mass (e.g., quartz crystal microbalance)24, optical properties (e.g., surface plasmon 
resonance)25 or electric field (e.g., field effect transistors)26. Thus far, these techniques 
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perform well when challenged with purified antibodies in simple buffers in a research 
setting. All these methods are easily operated, sensitive, and provide quantitative 
diagnostic information, however, they fail when challenged with realistically complex 
clinical samples, such as serum or whole blood. This reduces the efficacy and application 
for these different molecular diagnostic techniques at the point of care, namely because, 
as previously mentioned, further dilution or equipment intensive sample processing is 
required to distinguish between the background signal from non-specific adsorption and 
binding of target antibody. 
1.4 The gold standard diagnostic technique for detecting antibodies, ELISA 
Juxtaposed with current and developing point of care diagnostic techniques, the 
enzyme linked immunosorbent assay (ELISA) provides a highly sensitive, highly 
selective platform for detecting diagnostic antibodies and antigens in small volumes of 
minimally processed clinical samples. ELISA was developed in the 1960s when it was 
discovered that protein adsorbed to a solid surface through hydrophobic interactions was 
still able to participate in high affinity binding events, like the binding between an 
antigen and specific antibody27. A typical ELISA immobilizes either the target antigen 
(direct ELISA) or antibody (capture/sandwich ELISA) to a hydrophobic surface, such as 
a 96-well polystyrene plate, followed by stringent washing with buffer containing 
detergent. The ELISA is then blocked with a non-reactive, ubiquitous protein like 
albumin to prevent any antibody adsorption or interactions not directly related to binding 
between the target antigen-antibody pair. After an additional wash to remove unabsorbed 
blocking protein, the ELISA is incubated with a small volume (~100 µL) of the sample of 
interest. Following target sample incubation, the ELISA is again stringently washed, 
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before the addition of a reporter antibody. Reporter antibodies are primary and secondary 
antibodies that are conjugated with a small molecule or protein, such as biotin or 
horseradish peroxidase. After another stringent washing step to remove unbound 
conjugate antigen, the enzyme and/or substrate of the antibody conjugate is added to 
ELISA, wherein the resultant chemical reaction yields an observable signal, typically 
colorimetric28. These results are then interpreted using a spectrophotometer, where 
absorbance at a given wavelength is directly proportional to the concentration of 
antibody/antigen target in the sample27,28. 
 
Figure 4: Schematic of ELISA. Target biomolecule in the complex clinical sample interacts with the 
capture biomolecule (either antigen or antibody) which is immobilized on the solid phase. Unbound 
components of the sample are washed away. Secondary antibody with an enzyme reporter then binds the 
target biomolecule, with unbound secondary antibody washed away vigorously. Enzyme reporter substrate 
is then added and then the colorimetric signal change is read using a spectrophotometer. Figure taken from 
Carvalho et. al 2014.  
 
The application and utility of ELISA is extensive as it is easily multiplexed, 
highly sensitive and quantitative, and has a high signal to noise ratio. Firstly, due to the 
typical schematic of ELISA plates, multiple antigen-antibody pairs can be detected 
simultaneously against several different clinical samples with small variations in well-to-
well protocol. Second, because of the signal amplification that occurs with the reporter-
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antibody conjugate, the limit of detection for diagnostically significant antibodies can be 
within picomolar concentrations. Lastly, as the result of high-fidelity antigen-antibody 
binding, signal amplification, blocking to prevent non-specific adsorption, and extensive 
washing steps, complex clinical samples can be utilized in this diagnostic technique with 
excellent signal to noise. Because of these attributes, ELISA is currently the gold 
standard for immunodetection for most diseases6,19,29.   
Despite these positive attributes, ELISA is a laboratory intensive diagnostic 
technique that requires highly specialized technicians, well equipped facilities, expensive 
equipment for analysis, and most importantly, time. Each of the multiple steps of ELISA 
requires optimization: from buffer pH, to blocking and detergent concentrations in 
buffers, to serum dilutions to prevent signal saturation, to secondary protein conjugated-
antibody concentrations. Also, because of the numerous steps involved in ELISA and the 
high sensitivity, the potential for human error or contamination resulting in a false 
positive or negative result is high. As a result, highly trained technicians (or in a 
centralized facility, automated robots) with well established, clean workspaces are a 
requisite of successful ELISA experiments27,28. Furthermore, the standard instrument 
used for analyzing either the colorimetric or fluorescent results of ELISA, the Tecan 
Microplate Reader, is bulky and has a cost within the thousands of dollars. Lastly, as the 
result of multiple incubation and washing steps, the typical ELISA takes approximately 
four hours to complete at minimum if performed continuously30. 
1.5 Electrochemistry to detect diagnostic antibodies at the point of care 
As we previously described, current and even developing point of care diagnostic 
tests struggle to provide quantitative actionable diagnostic information and increase the 
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signal to noise ratio, while maintaining the high sensitivity, selectivity and multiplexing 
provided by the laboratory-bound gold standard ELISA. The development of 
electrochemical DNA (E-DNA) scaffold sensors may provide a solution to bridge the gap 
between current deficits in point of care technologies and laboratory approaches: 
providing a rapid, single step, quantitative, easily multiplexed platform for the 
measurement of specific antibodies17,31. 
Currently, E-DNA scaffold sensors are fabricated on a gold electrode surface that has 
been rigorously cleaned and etched through a series of oxidative and reductive steps. 
Taking advantage of the well understood gold-thiol chemistry32, a single stranded DNA 
molecule with a terminal (5’) reduced sulfur and a distal (3’) redox reporter (e.g., 
methylene blue or ferrocene) can be covalently attached to the gold surface17,31,33. After 
functionalization of our reporter strand, an anti-fouling self-assembled monolayer with a 
terminal thiol (e.g., mercaptohexanol, mercaptodecanol, biometric phospatidylcholine) is 
then used to back-fill the electrode, binding to the unoccupied gold on the electrode 
surface34. Finally, the DNA molecule is hybridized with a complementary peptide nucleic 
acid sequence (PNA) with a distal linear epitope which has been demonstrated (in peer-
reviewed experimental literature) to bind diagnostically-relevant antibodies. Once the E-
DNA sensor is fabricated, all that is required is to submerge the electrode in a small 
volume of an unprocessed clinical sample (e.g. 200 uL) in a single step and for a 
definitive positive or negative result. In the absence of the target antibody, the DNA-PNA 
scaffold allows the redox reporter to approach the electrode surface and exchange 
electrons when potential is applied in a window surrounding the reduction potential of the 
reporter. In the presence of target antibody, the non-covalent binding of the relatively 
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massive, heavy antibody (~150 kDa) to the epitope reduces the ability of the redox 
reporter to approach the electrode surface, which results in a decrease in current17,31,35 
(Figure 5).  
 
 
Figure 5: The E-DNA scaffold sensor in action. (Top) From left, the E-DNA scaffold built on the electrode 
surface before addition of the complex clinical sample. The DNA anchor strand with terminal redox 
reporter (methylene blue) is covalently linked to the gold electrode surface. A complementary PNA with a 
distal linear epitope hydrogen binds through nucleobases. In the absence of target antibody, this DNA-PNA 
approaches the electrode surface and the redox reporter is able to exchange electrodes. Upon addition of 
target, the binding of the large antibody to the relatively small DNA-PNA scaffold reduces its’ ability to 
approach the electrode surface, reducing the electron exchange between the gold surface and the redox 
reporter (Upper figure portion taken from White et al. 2012). (Bottom) The response (change in current) of 
the E-DNA scaffold sensor in the presence (black) and absence (red) of antibody as a function of potential. 
The response of the sensor in 100% serum and buffer is 48± 5% and 55± 2%, respectively.  
 
E-DNA scaffold sensors allow for rapid detection in two ways, 1) because we are 
measuring the sub-second electrochemical reaction of our redox reporter, and 2) the 
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binding of an antibody to its target epitope typically reaches equilibrium within a matter 
of minutes12,17. Typically, the signal gain by the sensor in response to the diagnostic 
antibody of interest in a positive unprocessed clinical sample ranges from 25-50%, 
whereas the background signal from non-specific adsorption of molecules in a negative, 
but similarly unprocessed clinical sample ranges from 8-15%17,36,37. This is due to the 
physical properties of the sensor; in addition to the anti-fouling monolayer, non-specific 
binding of other antibodies, serum proteins, platelets, and cells do not alter the dynamic 
interaction and electron transfer between the redox reporters in the sensor population and 
the electrode surface12,38,39. 
Through characterization of the E-DNA scaffold we are also able to obtain 
information regarding the limit of detection, the dissociation constant (KD), and 
determine antibody titer. In a paper published in our group by White and collaborators in 
2012, five E-DNA scaffold sensors were designed to detect antibodies indicative of the 
human immunodeficiency virus. When challenged, these sensors rapidly, specifically and 
selectively recognized their target antibodies at sub-nanomolar concentrations with KDs 
in the single digit nanomolar range, which is within the range of clinically relevant 
antibody concentrations17. Further development of one of these E-DNA scaffold sensors 
against the HIV envelope glycoprotein 41 (gp41) in our group by Patterson and 
collaborators was able to detect the antibody titer of a clinical sample, showed excellent 
agreement with commercially available recombinant immunoblot assay (RIBA), while 
out-performing the limit of detection for a commercially available LIA40.  
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Figure 6: Quantitative determination of the serum titer in a HIV positive clinical sample using the anti- 
gp41 E-DNA scaffold sensor (blue) as compared to commercially available LIA (top) and gp41 RIBA 
(red). While the LIA fails to detect dilute concentrations of the diagnostic gp41 antibody, the E-DNA 
scaffold sensor determination of serum titer closely matches the determination of serum titer of the 
commercially available anti-gp41 RIBA up to a two-thousand-fold serum dilution. Figure taken from 
Patterson et. al., unpublished.  
 
Multiplexing with E-DNA scaffold sensor can be accomplished with relative ease. 
Using lithography, electrodeposition, or wet chemistry, electrodes can be fabricated into a 
microarray to simultaneously detect multiple diagnostic antibodies and with positive and 
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negative controls31,41. In the academic setting, fabrication of these multiplexing 
microarrays becomes tedious and expensive, and hand-fabrication unfortunately 
promotes sensor to sensor variation and limits the compactness of the array, increasing 
requisite sample volumes. However, large scale production of these sensors using robotic 
microarray contact printers and a Biodot array printer will resolve these issues. With 
automation and the availability of portable, inexpensive, easy to use potentiostats42, this 
technology can be utilized at the point of care. This technology can be expanded to 
multiple different disease targets and serological markers in one, chip like device that 
would allow for multiplexed detection of multiple diseases in a small sample volume 
(~100 uL). Furthermore, automated fabrication of E-DNA sensors is inexpensive, with 
each sensor costing approximately $2US. 
1.6  Sexually transmitted infections and justification for use as our test bed 
As our test bed for validation of the E-DNA scaffold sensor, we have focused on 
the detection of antibodies diagnostic of sexually transmitted infections (STIs). Our 
reasoning is three-fold, 1) there exists a broad modality of infection and disease states, 2) 
STIs are extremely prevalent, well studied and development of a point of care diagnostic 
technology has high impact, and 3) because human samples, antibodies, and well 
established diagnostic immune tests are readily available. 
Sexually transmitted infections result from two types of pathogens, either 
bacterial or viral. Bacterial STIs include gonorrhea, chlamydia and syphilis, are curable 
with an appropriate course of medication. Viral infections include HIV, herpes simplex 
virus 1 (HSV-1), herpes simplex virus type 2 (HSV-2), hepatitis A virus (HAV), hepatitis 
B virus (HBV), hepatitis C virus (HCV), and human papillomavirus (HPV)—most of 
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which are incurable but for which treatment and management exists. During the course of 
infection, whether curable or incurable, antibodies are generated against the pathogen. 
Analysis of the immune history of a patient by detecting specific antibodies not only 
provides information about current infection but can provide information about past 
exposure and immunization history. 
According to the World Health Organization, an estimated 499 million new cases 
of curable STIs occur every year, an estimated 536 million people are estimated to be 
living with incurable HSV-2, and 219 million women are living with HPV43. Because of 
the large number of people from different regions and demographics affected by STIs, 
they have become the subject of extensive research and study. Comprehensive research 
exists on the structure and clinical course of these diseases, and extensive mapping of 
epitope mapping has been performed to aid in the development of diagnostic serological 
assays. In developed countries, such as the USA, screening for STIs is limited due to 
testing ease. For example, the Center for Disease Control reports that although 82% of 
women aged 15-24 that are sexually active receive contraceptive or STI testing, only 39% 
receive both44. Furthermore, only 27% of women seeking emergency contraception were 
screened for STIs, with 12% of them testing positive for at least one45. In developing 
countries, STIs are found with even higher frequency as a result of limited access to 
health care, diagnostic devices, and thus treatment. As such, there exists a need for rapid, 
uncomplicated diagnostic tests that can be performed with minimal, inexpensive 
equipment at the point of care to inform patients, improve outcomes and for easier 
epidemiological surveillance.  
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Here, we will take advantage of the prevalence and extensive study of STIs to 
develop our E-DNA scaffold sensor against high impact targets. Because of STI 
prevalence, authentic human samples indicative of a specific disease stage (acute 
infection, chronic infection, past exposure, immunized) from commercial vendors for 
research purposes is easily accessible. Furthermore, there are many vendors offering 
monoclonal and polyclonal antibodies against STIs for use as controls and or to 
determine limits of detection. Lastly, extensive immunodetection assays, such as ELISA 
and LIA, against a wide variety of antigen and antibody targets are available 
commercially. Many of these tests have undergone rigorous analysis by organizations 
such as the WHO and are recommended in the STI guidelines as the diagnostic standards 
for point of care and laboratory-based methods6,19,43. 
1.7 Internal controls for point of care E-DNA scaffold sensors 
 FLAG is a linear sequence of amino acids (DYKDDDDK) specifically developed for 
immunoaffinity chromatography. Because of its sequence, it does not interfere with the 
native folding of proteins, is water soluble and has a built in enterokinase-cleavage site for 
removal following protein purification. Furthermore, several monoclonal antibodies that bind 
flag have been raised, the most promising of which is the anti-flag monoclonal antibody M2, 
which is able to specifically and selectively bind the epitope in conditions mimicking 
biological environments (pH 7.6) without the presence of bivalent cations46. Because of its 
widespread use in immunochromatography, monoclonal antibodies against FLAG are readily 
available.  
Given the above, FLAG would work as an excellent internal control for our E-DNA 
scaffold platform. Previous work has demonstrated, incorporating the FLAG epitope into our 
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E-DNA scaffold sensor architecture results in a signal change of ~50% when challenged with 
saturating concentrations of monoclonal antibody17. Furthermore, because this is an artificial 
epitope, there is minimal chance of antibodies present in human clinical samples cross 
reacting to give false positives17.  
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Chapter 2: Structural modifications of the DNA-PNA Scaffold to improve  
analytical performance 
 
2.1 The current performance of the E-DNA scaffold sensor 
 As previously shown, the E-DNA scaffold sensor is able to detect diagnostically 
relevant antibodies in unprocessed clinical samples to provide actionable results at the point 
of care. White and colleagues demonstrated that five of the developed e-DNA scaffold 
sensors demonstrate a signal change of ~45% in response to a specific target antibody, in 
buffer and in complex clinical samples. However, while being able to sensitively and 
selectively detect target antibodies in a sub 15-minute time frame17, the result for the E-DNA 
scaffold sensor-antibody binding event is signal off, with a current change within the 
microamps. These sensors, while being able to detect clinically relevant concentrations of 
antibodies, would benefit from an increased limit of detection because it will decrease the 
time between infection and detection and improve the positive and negative predictive value 
of the test43. Thus, one of the first goals to improve the E-DNA scaffold sensor platform is to 
optimize two things: overall current and change in signal upon binding of the target antibody, 
and to improve the limit of detection. 
2.2 Structural modifications of the DNA-PNA scaffold to improve raw current and analytical 
sensitivity 
 While the mechanism of binding induced signal change by the E-DNA scaffold 
sensor is unknown, our group suspects this is due to a specific geometry of the antibody-
sensor complex. While this complex has not been visualized, from a bioengineering 
perspective we can experimentally modify this geometry and evaluate the potential to 
improve the raw current of the sensor and the binding induced signal change. 
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 The signal observed from E-DNA scaffold sensors is the result of a reduction of 
probability that the redox reporter will approach the surface on the electrode. Specifically, 
the current we observe as we scan the potential window surrounding the redox potential of 
our reporter is the population of sensor molecules able to approach the electrode surface and 
exchange electrons47. Upon binding of the comparatively large antibody to the E-DNA 
scaffold sensor, the probability that a redox reporter will approach the surface and thus 
exchange electrons is diminished, which we observe as a reduction in current. Because of 
this, we decided to utilize a voltammetric approach that is sensitive to changes in electron 
transfer kinetics, called square wave voltammetry. By slowing down the frequency of the 
potential applied to the system, we interrogate processes with a slower electron transfer rate 
with more sensitivity. While some DNA based electrochemical sensors are able to switch 
modalities from signal-on to signal-on by altering the frequency pulse, interrogation of the E-
DNA scaffold sensor with a frequency pulse between 1 and 10,000 Hz was unable to induce 
signal-on behavior17,48. Because electron transfer kinetics of the rigid E-DNA scaffold in the 
absence of antibodies is already a relatively slow process, high-gain signal-on behavior is 
believed to be possible when interrogating the sensor with frequencies below 1 Hz, where the 
signal to noise ratio is too low to provide reliable results. However, we are still able to 
observe signal-off behavior in the microamps with appreciable signal to noise when 
interrogating the electron transfer rate with slower frequencies between 5 and 120 Hz.  
To further improve electron transfer kinetics, thus increasing overall current and 
binding induced signal gain, we evaluated the effect geometric modifications of the sensor 
architecture and placement of the epitope relative to the redox reporter. As previously 
described, the E-DNA scaffold sensor consists of a double-stranded scaffold that is 
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completely complementarity. Because of this, the scaffold sensor duplex is assumed to be 
relatively rigid, even in the absence of target antibody, which one can assume reduces the 
ability for the redox reporter to approach the gold surface35. Furthermore, on both the 
reporter strand and the recognition strand, the attachment is made at the distal end, furthest 
from the electrode surface. While placement of the redox reporter has been shown not to 
significantly affect the electron transfer rates of a sensor duplex49, modifications in 
complementarity that increase the flexibility of the scaffold, or decreasing steric effects on 
the redox reporter by moving the antibody binding site, may increase the electron transfer 
kinetics and thus raw signal. Because of this, we designed and subsequently evaluated 
several scaffold sensors employing a variety of base pair mismatches. 
Due to cost (purchasing PNAs is in the thousands of dollars), DNA-DNA scaffold 
sensors were utilized to test this hypothesis. Utilizing the same 27mer DNA anchor strand 
with a distally attached methylene blue redox reporter, DNA strands with variable 
complementarity with a covalently linked immunogenic small molecule, digoxigenin, were 
used. As a negative control, we used the FLAG epitope displaying PNA. The first 
complementary sequence was a single stranded 27-base DNA with a distally linked 
digoxigenin that was completely complementary (Dig 1), which emulated the structure of 
previously published DNA-PNA scaffold sensor17. The second sequence was 27-base strand 
which employed a three base pair mismatch in the center of the construct with a distal 
digoxigenin (Dig 2). The third sequence was a 27-base strand with a distal digoxigenin 
containing a three base pair mismatch, followed by three complementary base pairs, followed 
by a second set of three mismatched base pairs, for a total of six base pair mismatches which 
were focused around the center of the construct (Dig 3). The fourth construct was a 10-base 
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strand with a distal digoxigenin that was complementary to the final ten residues of the 
anchor strand (Dig 4).  
After mechanical and electrochemical cleaning of the electrode, the sensor was built 
on the surface using previously established protocols17. In short, 25 nM of DNA anchor in 
phosphate buffered saline was allowed to functionalize on the electrode surface for one hour 
at room temperature. This was followed by an overnight functionalization of a 6-
mercaptohexanol SAM in phosphate buffered saline at 4°C. The following morning, the 
electrode was submerged in the 200 nM of the appropriate digoxigenin conjugated DNA in 
phosphate buffered saline for two hours at room temperature to allow the DNA strands to 
anneal.  
As one of our goals was to determine if changes in complementarity, and thus 
flexibility, of the scaffold sensor affected the raw signal output, the signal (raw current) after 
annealing of the DNA complement was evaluated. This was accomplished by scanning the 
electrodes with differing complement constructs in triplicate, using square wave voltammetry 
(frequency of 60 Hz, amplitude 25 mA17,40) in 3x phosphate buffered saline after 20 minutes 
equilibration (Figure 7). From the figure we see that compared to the FLAG scaffold sensor 
and the other digoxigenin constructs, the Dig 4 construct nearly doubles the raw current. 
Unfortunately, based on these results, we see that even with these changes in 
complementarity of the sensor, the raw current observed is still within the microamp range, 
which is not a sufficient improvement over the currently utilized sensor architecture.  
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Figure 7: The effects of increased scaffold sensor flexibility on raw current. As seen above, while the shorter 
Dig 4 construct nearly doubles the raw current from the fully complementary Dig 1, the signal is still within the 
microamp regime, which is not a significant improvement over the current working construct. Data points are 
comprised of an average and the error bars represent the standard error (n=3). 
 
After evaluation of the raw current as affected by changes in scaffold 
complementarity, the electrodes were immediately challenged with a saturating concentration 
of anti-digoxigenin monoclonal antibody, spiked into the 3x phosphate buffered saline to a 
final concentration of 30 nM. These electrodes were then scanned every 15 minutes over the 
course of an hour (Figure 8). As anticipated, the FLAG scaffold sensor showed no response 
outside of expected drift (4%), and the Dig 1 construct showed a signal change of 35%, 
which is within the realm of expectation for our antibody-scaffold sensor binding. However, 
modifications in sensor architecture by introducing base pair mismatches demonstrated a 
negative effect on signal gain. From the results we see that even the best performing of the 
base pair mismatch constructs, Dig 2, still underperformed the traditional sensor architecture 
by 10%.  
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Figure 8: The effects of increased scaffold sensor flexibility on signal gain. The figure above illustrates signal 
gain as a function of time in the presence of 30 nM anti-digoxigenin monoclonal antibody for the four dig 
constructs of variable complementarity displaying a distal digoxigenin. As seen above, the completely 
complementary scaffold, with no bp mismatches, undergoes the largest signal change in response to saturating 
concentrations of anti-digoxigenin monoclonal antibody. The FLAG E-DNA scaffold sensor was used here as a 
control. Data points are comprised of an average and the error bars are the standard error (n=3). 
   
2.3 Use of a bivalent epitope in the E-DNA scaffold sensor to improve analytical sensitivity 
While our E-DNA scaffold sensor has shown to be able to detect diagnostically 
significant concentrations of antibodies in complex clinical samples, improving the limits of 
detection will allow for earlier diagnosis and subsequently improved patient outcomes. 
Previously published results using the E-DNA scaffold sensor employ only a single 
covalently linked linear epitope17,31,40. However, the structure of an antibody has two antigen 
binding domains which are spaced approximately 11.7 to 13.4 nm apart, where the epitope 
distance range is dependent on inherent flexibility in the antibody structure50. Taking 
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advantage of these two antibody binding sites could improve the sensor’s affinity for its 
target, lowering its limit of detection. 
In response to the above, an E-DNA scaffold sensor was designed with two linear 
epitopes presented on a single strand. Based on the distance between the antigen recognition 
sites, two PNAs presenting the FLAG linear epitope were designed with 10 base pairs 
complementarity to a DNA anchor strand, spaced approximately 12 nm apart. Due to the 
reduced number of DNA base pairs used to form the DNA-PNA duplex, the GC content of 
the duplex was raised to 70%, as opposed to the 26% used in previously published scaffold 
sensors17, to increase the number of hydrogen bonds and thus increase of the stability of the 
DNA-PNA duplexes upon binding of the target antibody. 
 The bivalent epitope sensor was built on electrode surface using the same electrode 
preparation described in the section above, except the DNA anchor for the control and the 
bivalent FLAG sensor was annealed with 400 nM of PNA rather than of 200 nM, taking into 
account a doubling of number of duplexes on the DNA molecule. The electrodes were then 
placed into 3x phosphate buffered saline, where they were allowed to equilibrate for 20 
minutes before being challenged with 60 nM of anti-FLAG monoclonal antibody, a 
concentration well above saturating. The sensor response to antibody was measured again at 
60 Hz with an amplitude of 25 mV. However, the bivalent epitope (bivalent flag) performed 
very poorly when compared to the original sensor architecture (monovalent flag), 
demonstrating a 4% signal change versus 26% signal change in 15 minutes point of care 
window (Figure 9).  
 The main advantage that we hoped to gain by creating a bivalent epitope sensor was 
improved detection limits, ideally in complex samples. This was tested by challenging the 
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bivalent and monovalent epitope FLAG scaffold sensors with 5 nM of anti-FLAG 
monoclonal antibody under two conditions, one being 3x phosphate buffered saline, and the 
other being 3x phosphate buffered saline spiked with normal human serum to a concentration 
of 10%. After allowing the sensors to equilibrate in their electrochemical cells for 20 minutes 
to adequately remove any background signal from nonspecific adsorption, the sensors were 
scanned every five minutes for one hour following the addition of 5 nM anti-FLAG 
monoclonal antibody. As seen in Figure 10, while there is no appreciable response to the 
anti-FLAG antibody within our previously defined point of care window, the monovalent 
FLAG sensor in both the phosphate buffered saline and 10% human serum undergoes an 
appreciable signal change (~30%) in one hour. In comparison, the bivalent FLAG sensor 
only undergoes a 10% change in signal in the same amount of time.  
 The two most plausible reasons for the failure of the bivalent epitope sensor stem 
from either an ineffective architectural design of the scaffold, or changes in electron transfer 
rate, which means the new sensor requires optimization of the electrochemical interrogation 
parameters. The two main parameters that affect square wave voltammetry, and thus sensor 
gain upon binding of the target antibody, are frequency and amplitude. Using these two 
parameters, we can “tune” the electrochemical interrogation to optimize the signal gain of 
our sensors48. This said, we find that frequencies below 5 Hz produce poor signal to noise 
and that, because the transfer rate is relatively slow, frequencies above 500 Hz produce very 
little gain; thus we limited the frequency of our potential pulse between 5 and 500 Hz. 
Similarly, because amplitudes below 10 mV produce poor signal to noise and amplitudes 
above 100 mV cause substantial peak widening, we limited our amplitude investigation to 
this range. As we can see in Figure 11, within the range of electrochemical conditions that 
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work best for this sensor type48, at saturating concentrations of monoclonal antibody the 
monovalent FLAG sensor (a) outperforms the bivalent FLAG sensor (b) by 30%. 
 
Figure 9: Performance of the bivalent epitope sensor in the presence of saturating target monoclonal antibody 
concentration. Bivalent FLAG epitope sensor is challenged with saturating concentrations (30 nM) of anti-
FLAG monoclonal antibody with the monovalent FLAG epitope sensor as a control. As illustrated in the figure, 
the distal display of the monovalent FLAG epitope with completely complementary PNA significantly 
outperforms the bivalent FLAG epitope sensor with ten base pair complementarity, undergoing a signal change 
of 26% and 5% in fifteen minutes, respectively. Data points are comprised of an average and the error bars are 
the standard error (n=3). 
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Figure 10: Performance of the bivalent epitope antibody sensor in the presence of low target antibody 
concentration. As indicated by the figure, bivalent epitope probes also do not improve the detection of 
antibodies at low concentrations. In buffer and 10% serum in the presence of 5 nM anti-FLAG monoclonal 
antibody, the monovalent FLAG epitope scaffold sensor outperforms the bivalent FLAG epitope scaffold 
sensor, undergoing a signal change of 30% compared to a signal change of 10% over the course of an hour. 
Data points are comprised of an average and the error bars are the standard error (n=3). 
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Figure 11: Frequency and amplitude tuning of the monovalent and bivalent FLAG epitope scaffold sensor. This 
is performed by taking the difference of all the signal output (current in microamps) for all of the frequency (5 – 
500 Hz) and amplitude (10 – 100 mV) combinations in the absence and presence of saturating concentrations of 
anti-FLAG monoclonal antibody (30 nM) in phosphate buffered saline. (a) Frequency vs amplitude map of the 
monovalent FLAG epitope scaffold sensor. As illustrated by the figure, the maximum signal gain of the 
monovalent FLAG scaffold sensor is 55% and occurs at a frequency of 5 Hz and amplitude of 10 mV. (b) 
Comparatively, the maximum signal gain of the bivalent FLAG scaffold sensor occurs at a frequency of 120 Hz 
and amplitude of 10 mV, with a maximum binding induced signal gain of 25%. 
 
2.4 Interpretations of results and conclusion 
Detection limits are a function of both the gain of the sensor and the affinity of its 
receptor. Based on the results obtained (Figures 8-11), we conclude that the modifications 
utilized here with increased scaffold sensor flexibility and this bivalent epitope sensor 
architecture reduce signal gain enough to harm the limit of detection rather than improving it. 
However, only a few modifications to the E-DNA scaffold sensor architecture were 
investigated; future changes of the complementarity, length and placement of the redox 
reporter and integration of a second epitope may provide further improvements of the E-
DNA scaffold sensor. 
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Chapter 3: Expansion to multiple disease biomarkers 
3.1 Diagnosis of viral sexually transmitted infections using the E-DNA scaffold sensor 
 While sexually transmitted diseases are extremely prevalent, developed countries 
with access to routine healthcare and gold-standard STI testing methods (often government 
subsidized) typically see those infected receiving treatment, disease management, and a plan 
for long term follow up—all of which improve outcomes and quality of life while reducing 
disease transmission51. In rural or impoverished areas, in contrast, access to medical 
professionals and well-equipped diagnostic laboratories, and therefore treatment and long-
term disease management, is often limited or even non-existent. Because of these factors, 
poor and geographically remote areas in developing countries are those with high prevalence, 
high mortality and increased risk of STI transmission. This high risk-low medical attention 
scenario is also mirrored by people displaced following natural disasters and refugees. 
Additionally, groups experiencing social stigma or living high-risk lifestyles, such as 
homosexuals, transgendered individuals, intravenous drug users, and sex workers, are seen to 
have a statistically significant higher prevalence of STIs, even in developed countries6,19,43,52. 
 By increasing the efficiency of diagnosis, easily utilized point of care diagnostic 
devices that can be employed with minimal sample processing and no specialized training 
will reduce the number of patients in all demographics living with STIs and reduce 
transmission rates in these areas where routine health care is limited or interrupted. If a 
definitive diagnosis can be made before a patient is lost to follow up, treatment may 
eliminate a bacterial STI, or anti-viral therapies may prolong a patient’s quality and length of 
life by decades53. We begin our expansion of the E-DNA scaffold sensing platform here, with 
32 
 
the aim of creating a point of care diagnostic tool that can detect multiple disease biomarkers 
in complex, minimally processed samples.  
 While incorporation of a full immunogenic antigen into our scaffold sensing 
architecture would allow for the detection of monoclonal and polyclonal antibodies for linear 
and conformational epitopes, our group has demonstrated that the signal gain of the scaffold 
sensor in response to the target antibody is directly proportionate to the size difference 
between the antigen/epitope displayed and antibody. Thus, utilization of short linear epitopes 
instead of full length or even truncated antigens provides an appreciably larger change in 
current as the result of a binding event37. Further, for this to be a viable diagnostic platform, 
considerations regarding sensor stability between fabrication and utilization at the point of 
care must be taken into account. Utilization of full-length or truncated proteins (but still 
folded) in our scaffold sensor presents several problems, most of which stem from the 
stability of a folded protein. Changes in temperature, electrolyte composition, and most 
importantly, time, affect a protein’s ability to maintain its native, and therefore antigenic, 
structure54. The use of a linear, immunodominant epitope eliminates the problems that stem 
from maintaining a native state protein, and the E-DNA scaffold sensor employing linear 
epitopes for antibody detection have been shown to be stable over several weeks17,31. Our 
strategy for expanding the repertoire of diagnostic biomarkers in the E-DNA scaffold sensing 
platform is thus through identification of linear, immunodominant epitopes identified from 
the peer-reviewed literature. 
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3.2 Diagnosis of the human immunodeficiency virus using the E-DNA scaffold sensor 
One of the most infamous, well studied, and high impact of the STIs is the human 
immunodeficiency virus (HIV), and the advanced and lethal state of HIV infection, acquired 
immunodeficiency syndrome (AIDS). As of the end of 2017, 36.9 million people are living 
with HIV, 1.8 million new people become infected with the virus each year, and in 2017 
940,000 people died from HIV related causes globally43. However, with improvements in 
diagnostic speed and accuracy, patients have been able to make informed decisions to 
prevent the spread of HIV, with the rate of new HIV infections falling by 36% over the last 
17 years55.  
Upon infection with HIV, the immune system undergoes an adaptive immune 
response against the pathogen: cell mediated immunity mediated by T lymphocytes, and 
humoral immunity mediated by antibodies produced by B cells11. Due to the structure and 
pathology of HIV, neutralizing antibodies from cell-mediated immunity are ineffective at 
killing the virus. Both these antibody types, however, are nevertheless of significant 
diagnostic importance. As the infection progresses the body produces an infection versus 
time dependent antibody profile against different HIV envelope proteins. Two of the most 
utilized diagnostic antibodies in clinical samples after infection with HIV are the early 
detection anti-p24 antibody, which shows up within a month after infection and disappears 
after six months, and the anti-gp41 antibody, which appears after four months and remains 
throughout the course of infection56. Based on these two antigen-antibody pairs, both lateral 
flow, point of care immunoassays and laboratory ELISAs have been developed and are 
widely employed in the diagnosis of HIV infection43,55,57. 
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 Although a literature search to identify linear epitopes in p24 identified no single 
immunodominant sequence, ample literature exists identifying a linear immunodominant 
epitope for the anti-gp41 antibody found in humans17,43,58. This linear epitope was identified 
via synthetic peptide epitope mapping, and further literature utilizing this identified antigenic 
peptide demonstrated excellent specificity and selectivity challenged with complex clinical 
samples17,59. The anti-gp41 antibody was found to recognize the amino acids CSGKLVC, 
and a human commercially available monoclonal antibody has been developed for purchase 
from Polymun Scientific for use as a positive control. Based on extensive literature showing 
this as a diagnostically significant peptide and the presence of a monoclonal antibody, this 
linear epitope was incorporated into E-DNA scaffold sensor platform, where we included an 
additional five amino acids taken from the original sequence of gp41 (LWGCSGKLVCTT) 
to minimize steric interactions.  
 The first experiment to validate the gp41 epitope sensor was to utilize a high affinity-
custom designed ELISA to determine the binding potential and diagnostic predictive value of 
our PNA-epitope chimera when challenged with HIV positive and negative serum samples 
(see methods). Utilizing a 1:40 dilution of human serum and an anti-human horse radish 
peroxidase (HRP) conjugated secondary antibody, the scaffold sensor with and without the 
PNA was challenged using our ELISA protocol. As indicated by the results (Figure 12) the 
scaffold sensor with PNA was able to identify and differentiate between all of the positive 
samples and the negative controls. Background signal in the wells without the PNA 
containing epitope, due to non-specific adsorption of antibodies present in human serum, was 
relatively low and did not provide any false positives. Based on these ELISA results, we 
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anticipated that our E-DNA scaffold sensor would similarly achieve > 95% positive and 
negative predictive value as required by WHO rapid test guidelines43,53,60. 
 
 
Figure 12: Custom PNA scaffold ELISA of the gp41 immunodominant epitope against HIV seropositive and 
seronegative patient samples. In red is the background signal due to nonspecific adsorption in the absence of the 
PNA and linear epitope, and in orange with have the signal with the PNA and anti-gp41 linear 
immunodominant epitope due to antibody-epitope interactions. As demonstrated by the figure above, this linear 
epitope demonstrates positive and negative predictive value for HIV positive and negative serum sample by 
ELISA. Data points are comprised of an average and the error bars are the standard error (n=3). 
 
 With the positive results from ELISA indicating diagnostic success for the gp41 
PNA, next step was to evaluate its success on the electrode surface. More importantly, we 
want to demonstrate that it is the presence of the anti-gp41 diagnostic antibody, and not the 
other antibodies or components of complex clinical samples that gives rise to an observable 
signal. Anticipating less sensitivity than an ELISA, the gp41 sensor was challenged with 1:10 
dilutions of either known HIV positive human serum (patient 1 in ELISA) or known HIV 
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negative serum in buffer (3x phosphate buffered saline, 0.05% Tween-20, 1% bovine serum 
albumin). Next, the antibodies in HIV positive serum were removed using a protein G spin 
trap, and the sensor was challenged with the antibody depleted serum. Finally, the sensor was 
challenged with 30 nM of the commercially available anti-gp41 antibody that was spiked into 
HIV negative serum. For each of these conditions, the electrodes in triplicate were allowed to 
equilibrate for thirty minutes before interrogation via square wave voltammetry at a 
frequency pulse of 100 Hz and amplitude of 25 mV17. The FLAG epitope scaffold sensor was 
used as a negative control.  
The results (Figure 14) indicate that the gp41 scaffold sensor has a signal gain of 
~38% when challenged with dilute positive serum from patient sample 1. Comparatively, 
when challenged with dilute known negative serum and antibody removed positive serum, 
the gp41 scaffold sensor only exhibits of signal change of ~8%. Lastly, when the sensor is 
challenged with the dilute HIV negative serum spiked with anti-gp41 monoclonal antibody, 
we again see an appreciable, diagnostically significant signal of ~25%. The FLAG sensor 
throughout, and the signal of the gp41 sensor in response to negative and antibody depleted 
serum, was consistently under 10%. Based on the complexity of clinical samples, even when 
dilute, it is within the realm of expectation that these relatively low changes in signal are due 
to the nonspecific adsorption that occurs in complex samples.  
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Figure 13: The gp41 E-DNA scaffold sensor selectively binds antibodies specific to HIV infection. This figure 
illustrates the electrochemical response of the gp41 scaffold sensor to positive serum, negative serum, antibody 
depleted positive serum, and negative serum spiked with commercially available human anti-gp41 antibodies. 
As demonstrated by the figure, the gp41 scaffold sensor has a gain of 38% in positive serum yet does not 
respond to HIV negative human serum (8%) or HIV positive serum with the antibodies removed (6%). When 
challenged with anti-gp41 monoclonal antibodies in negative serum, the sensor again demonstrates a 
diagnostically significant signal of 24%. In all scenarios, the FLAG scaffold sensor does not display a signal 
gain of more than 10%, which is within the realm of signal gain due to nonspecific adsorption in complex 
clinical samples. All of the serum samples evaluated above were diluted 1:10 in buffer. Data points are 
comprised of an average and the error bars are the standard error (n=3). 
 
  To further validate our sensing platform and its utilization for point of care 
diagnostics, equilibration time and sensor binding kinetics in a complex clinical sample was 
studied. To accomplish this, the gp41 and FLAG sensors were challenged with 1:10 diluted 
negative human serum in 3x phosphate buffered saline. This solution was then spiked with 
saturating concentrations (30 nM) of human anti-gp41 monoclonal antibody. The electrodes 
were scanned using square wave voltammetry at a frequency of 100 Hz and amplitude of 
25mV. Plotting signal change as a function of time, we see rapid equilibration of the gp41 
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sensor in the presence of saturating concentrations of target antibody (Figure 14). Within the 
15-minute point of care diagnostic window, we see that while the control FLAG sensor 
exhibits a signal change of ~5%, the gp41 signal changes by ~25%. These results 
demonstrate that the equilibration of the gp41 sensor is rapid enough to provide actionable 
diagnostic information within the short time frame consistent with point of care applications. 
 
Figure 14: Rapid equilibration of the gp41 E-DNA scaffold sensor. Kinetic study of the gp41 and FLAG sensor 
in negative serum with saturating concentrations of the human anti-gp41 monoclonal antibody (30 nM). Within 
15 minutes the gp41 scaffold sensor (red) exhibits a signal gain of 18%, whereas the signal gain by the control 
FLAG scaffold sensor (black) is less than 5%. Data points are comprised of an average and the error bars are 
the standard error (n=3).  
 
As demonstrated in the prior two figures, the gp41 scaffold sensor selectively, 
specifically, and rapidly binds to anti-gp41 antibodies present only in HIV positive serum, 
for at least one sample. To further expand this claim, under identical serum dilution and 
electrochemical conditions described for the previous experiment, we challenged the gp41 
scaffold sensor with the remaining patient serum samples used in the ELISA after allowing 
electrodes to equilibrate for 20 minutes. As seen in Figure 15, all but two of known positive 
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HIV serum samples did not provide a diagnostically significant electrochemical signal (e.g., 
did not have a signal at least one standard deviation higher than the negative control). For the 
electrodes that did produce a diagnostically significant signal, the signal change varied 
between ~16 and 28%. Overall, 84% of patient serum samples that were identified 
seropositive for anti-HIV antibodies, both by the supplier and by our ELISA, elicited a 
diagnostically actionable electrochemical signal. We believe this false-negative response to 
be due to a concentration of anti-gp41antibody that is below the limit of detection for our 
sensors. Because ELISA is orders of magnitude more sensitive than our electrochemical 
tests, it is reasonable to speculate that ELISA would be able to detect diagnostically 
significant concentrations of antibodies where our sensor would not.  
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Figure 15: Electrochemical response of the gp41 E-DNA scaffold sensors to various known positive and 
negative patient serum samples. Out of twelve known HIV positive serum samples, the gp41 E-DNA scaffold 
sensor demonstrated significant signal gain to positively identify ten samples, with two serum samples 
demonstrating low signal gain that is within one standard deviation of the negative control, HIV negative serum.  
Data points are comprised of an average and the error bars are the standard error (n=3). The high error bars here 
are likely due to sensor-to-sensor variability, which is the result of hand fabrication of electrodes. 
 
3.3 Diagnosis of hepatitis C infection using the E-DNA scaffold sensor 
 Infection by the hepatitis C virus (HCV) produces liver disease with two modalities: 
acute, which results in mild illness lasting several weeks, or chronic, which is a lifelong 
illness. While both modalities are serious, chronic HCV typically results in permanent liver 
damage, which manifests as either chronic cirrhosis or hepatic cancer.  Per WHO statistics, 
chronic HCV affects an estimated 71 million people globally, with approximately 400,000 
deaths and 1.75 million new infections annually55. In recent years, antiviral therapeutics have 
been developed which can cure approximately 95% of patients living with the chronic 
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disease. Limited access to diagnostic assays and medical treatment still makes HCV 
extremely prevalent. Like HIV, high-risk demographics, including intravenous drug users 
and commercial sex workers, have higher infection and transmission rates. Additional modes 
of transmission include inadequate sterilization of medical supplies and tainted blood 
transfusions61.  
 Most people experiencing acute HCV infection are asymptomatic, and even people 
with chronic infections can remain asymptomatic for decades62. Surprisingly, between 15 and 
45% of people who contract the disease clear the virus without medical intervention. Because 
of spontaneous clearance of the virus due to a strong immune response, which can result in a 
lifetime presence of anti-HCV antibodies, people exhibiting symptoms of HCV are often 
given two tests43. The first diagnostic test is ELISA against anti-HCV antibodies. Because 
there is not clear immunogenic prevalence for one protein of HCV, first, second and third 
generation ELISAs have all employed a variety of recombinant epitopes from multiple 
antigens, or multiple full-length antigens62. If the anti-HCV antibody ELISA is positive, a 
secondary test is performed which uses a PCR reaction to test for the presence of hepatitis C 
viral RNA. In the case of a positive ELISA and a negative HCV PRC reaction, a RIBA is 
performed which tests for the presence of antigen specific anti-HCV antibodies. This test is 
typically employed to determine if the patient has a resolved HCV infection of a biological 
false positive ELISA63. Diagnosis of HCV using ELISA, PCR and RIBA is an intensive, time 
consuming processes that requires trained technicians and expensive equipment to perform62.  
Only within the last two years has the first point of care diagnostic test been 
prequalified for use by the WHO to aid in the diagnosis of HCV in low income and 
developing countries64. This device is a LIA that utilizes three of HCV’s ten proteins62 for 
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diagnosis in complex samples in 20 minutes. When compared to the commercially available 
RIBA, the new point of care LIA only demonstrated 78.8% sensitivity. In contrast, however, 
it achieved 100% specificity when challenged with clinical samples positive for hepatitis B 
and other potentially cross-reactive diseases20. While being the first of its kind, the low 
sensitivity and high number of target antigens used in this HCV diagnostic LIA necessitates 
secondary testing and larger blood volumes with diagnostic times outside the point of care 
window3.  While this test meets the WHO criteria ASSURED, improved sensitivity for the 
point of care detection of anti-HCV antibodies is necessary to increase diagnostic efficacy 
and assist in the eradication HCV. 
One of the HCV proteins that has consistently been employed in multiple generations 
of ELISA and RIBA to diagnose HCV is the core protein62. Epitope mapping of this protein 
using synthetic peptides challenged with 96 human serum samples (50 positives and 46 
negatives by full-length antigen ELISA) indicates two overlapping linear immunodominant 
sequences. The first consists of amino acids 1-18 and exhibits 80% clinical specificity and 
the second spans from amino acids 11-28 and exhibits 82% specificity, where both 
demonstrated 100% clinical sensitivity by ELISA. When these two synthetic peptides were 
employed in tandem (as separate peptides) and tested against the same set of 96 serum 
samples, they yielded 92% specificity while maintaining 100% selectivity65. Further study 
over the next decade by multiple independent research groups consistently demonstrated the 
same findings7,66–68. Based on these results found in the literature, the two overlapping linear 
epitopes, consisting of amino acids 1-28 of the HCV core protein 
(MSTNPKPQRKTKRNTNRRPQDVKFPG), were incorporated into our E-DNA scaffold 
sensor architecture.  
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Our first experiment to determine the ability of our HCV PNA to detect anti-HCV 
antibodies indicative of infection and differentiate them from normal human serum, was the 
ELISA. Using the protocol described in the methods, the HCV PNA was challenged with 
1:80 dilutions of known positive and negative serum samples using FLAG as an additional 
negative control. As seen in Figure 16, when compared the absorbance to HCV negative 
serum, seven of the ten known seropositive samples were highly reactive to the HCV PNA, 
whereas one was moderately reactive, and two samples were nonreactive. However, this 
result is within the realm of acceptability, namely because previous studies that tested the 
diagnostic potential of this epitope used significantly more samples, and the specificity of 
this epitope has not been shown to be 100%.  
 
44 
 
 
Figure 16: Custom PNA scaffold ELISA of the HCV PNA against HCV seropositive and seronegative patient 
samples. As illustrated by the figure, eight out of ten serum samples were identified as positive using our linear 
immunodominant epitope, with the remaining two serum samples providing a signal that was less than, or 
within one standard deviation of the negative control, normal serum. The FLAG PNA was used as a control, 
demonstrating no cross-reactivity between the FLAG epitope and the HCV seropositive samples. Data points 
are comprised of a three well average and the error bars are the standard error. 
 
Based on the reactivity of the sensor by our custom ELISA, the HCV PNA was 
incorporated into our E-DNA scaffold sensor and challenged with the same clinical samples 
used in above ELISA. Using square wave voltammetry at a frequency of 60 Hz and 
amplitude of 25 mV, the E-DNA scaffold sensor containing the HCV PNA failed to 
demonstrate a diagnostically significant signal gain in response to anti-HCV antibodies from 
HCV positive patients two, three and eight when compared with the control FLAG PNA 
(1:10 diluted serum in 3x phosphate buffered saline) (Figure 17). Even though these were the 
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most reactive patient samples by ELISA, and even with repetitions of this experiment where 
nonspecific adsorption was blocked on the electrode surface (using 3x PBS, 0.05% tween-20, 
1 mg/mL fibrinogen), the sensors failed to respond appreciably to HCV positive serum. 
 
 
Figure 17: Electrochemical response of the HCV scaffold sensor over an hour to 1:10 diluted normal serum and 
HCV seropositive patient samples. Based on the results presented in the figure, there was no statistically 
significant signal gain by the HCV scaffold sensor (right) in response to known positive serum samples two 
(orange), three (grey), or eight (white) when compared to normal serum (red) and to the response by the control 
FLAG scaffold sensor (left). Sensor batch assembly and functionality success was verified by challenging the 
HCV and FLAG scaffold sensors in 1:10 diluted normal serum spiked with saturating concentrations (30 nM) of 
anti-FLAG monoclonal antibody (black). As seen, the control FLAG scaffold sensor underwent a signal gain of 
48% (net 30%) over the course of an hour in response to anti-FLAG monoclonal antibody, indicating the 
scaffold sensors were successfully built on the surface. Data points are comprised of a three-electrode average 
and the error bars are the standard error. 
 
Because the ELISA is orders of magnitude more sensitive than our E-DNA scaffold 
sensor it is possible that the concentration of anti-HCV antibodies present in these HCV 
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patient serum samples is below the limit of detection of the E-DNA scaffold sensor. While 
this process does require significant processing of clinical samples, 1 mL of serum from 
patient samples two, three, and five underwent antibody removal using a protein G spin trap 
and were subsequently concentrated using a 15 kDa centrifugal filter unit. The HCV and 
FLAG scaffold sensors were than challenged with these concentrated antibodies at a final 
concentration of ten times the concentration of 100% serum (henceforth referred to as 10x 
concentrated antibodies) in 3x phosphate buffered saline under identical square wave 
voltammetry experimental conditions. As seen in Figure 18, when compared to the FLAG 
control, the HCV scaffold sensor does not exhibit any specific, binding-induced signal 
change in response anti-HCV antibodies, even when concentrated. Even if the HCV sensor 
were able to detect removed, concentrated anti-HCV antibodies, the significant post 
collection sample processing required would eliminate the epitope used in this HCV scaffold 
sensor for use as a point of care diagnostic test. 
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Figure 18: HCV scaffold sensor challenged with antibodies removed and concentrated from the four most 
reactive HCV seropositive patients by ELISA (patients 2,3,5 and 8). Antibodies were removed using a protein 
G spin trap and concentrated using size exclusion protein concentrators. Removed and concentrated antibodies 
from the HCV serum were spiked into 3x phosphate buffer to a final concentration of ten times their 
concentration in 100% serum. As demonstrated by the figure, there is no statistically significant signal gain by 
the HCV scaffold sensor (red) in the presence of removed and concentrated antibodies buffer when compared to 
the response of the FLAG scaffold sensor (black) and the HCV scaffold sensor in 1:10 diluted normal serum in 
3x phosphate buffer (orange). All signal gain can be attributed to drift, as evidenced by nearly identical signal 
gain by the FLAG scaffold sensor and HCV scaffold sensor in 1:10 diluted normal serum. Data points are 
comprised of an average and the error bars are the standard error (n=3). 
 
3.4 Diagnosis of the herpes simplex type 2 virus using the E-DNA scaffold sensor 
Herpes simplex virus (HSV) is an increasingly common, highly contagious disease 
affecting approximately half a billion people between the ages of 15-4943,52. Two genetically 
distinct variations of the HSV exist, types 1 (HSV-1) and two (HSV-2). A common 
misconception is that HSV-1 is solely responsible for oral herpes and HSV-2 is solely 
responsible for genital herpes, when in actuality both variations of the virus can infect the 
same anatomical area69. However, HSV-2 infections have a much higher recurrence rate (~5x 
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greater), and thus symptoms leading to repeated clinical visits which prompt diagnostic 
testing usually are the result of the HSV-2 variant6. Unfortunately, patients presenting with 
symptoms are often the only ones with the disease diagnosed by a clinician, with diagnosis 
rates between 13 and 37%, despite the high prevalence of the disease. Simply put, patients 
not experiencing HSV symptoms are not typically tested for the disease and can go 
undiagnosed for years. However, patients not presenting with HSV symptoms who are 
known positives for other sexually transmitted infections typically have a higher testing 
frequency and therefore higher diagnosis rate70,71. 
The primary antigen used to detect anti-HSV-2 antibodies and to differentiate 
between HSV-2 infection and infection with the closely related HSV-1 is a highly 
immunogenic external glycoprotein G2 (gG2)72,73. Current diagnosis of asymptomatic HSV-2 
is performed in two phases: the first, which provides a preliminary diagnosis and immediate 
actionable information, is a LIA against gG2 specific antibodies74, the second, which 
confirms the diagnosis, is a gG2 specific ELISA75. Epitope mapping using overlapping 
synthetic peptides of gG2 identified a 19 amino acid sequence with excellent clinical 
sensitivity and specificity when used in ELISAs74,76–78. Here we incorporated this 
immunodominant epitope (PEEFEGAGDGEPPEDDDS) into our scaffold sensor platform to 
electrochemically detect anti-HSV-2 antibodies in serum. 
The first test of our sensor was to determine if the sensor can differentiate between 
HSV-2 positive and negative serum using our custom ELISA. To test this, we challenged the 
sensor with 12 known seropositive and one seronegative clinical HSV-2 samples. While the 
gG2 linear epitope was able to distinguish between known positive and negative clinical 
samples at a 1:10 dilution (Figure 19), there are two concerning aspects of this data: 1) the 
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signal of the ELISA is extremely low in known positive serum samples at a relatively high 
concentration of serum and 2) the most reactive of the positive patient samples exhibit a 
signal gain of approximately twice that of the negative control.  
 
Figure 19: Custom PNA scaffold ELISA of the HSV-2 immunodominant epitope against HSV-2 seropositive 
and seronegative patient samples. As illustrated by the figure, all the serum samples were identified as positive 
using our linear immunodominant epitope when compared with a negative control, HIV positive patient sample 
6. It is important to note that while all twelve of the known positive serum samples here are definitely identified 
as positive using the HSV-2 PNA, the absorbance values are significantly lower than those usually seen by 
ELISA, with repetitions of this experiment yielded similar results. Data points are comprised of a three well 
average and the error bars are the standard error. 
 
Nonetheless, based on the above result the gG2 linear epitope was incorporated into 
the scaffold sensor architecture on the electrode surface and challenged with 1:10 dilutions of 
known positive and negative serum. Initial results, which are not included here, showed 
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substantial variability in signal when the HSV-2 scaffold sensor was challenged with the 
same 1:10 diluted pooled sample of negative serum (6 to 35% signal change). Based on the 
results from the ELISA experiment, the scaffold sensor was challenged with the two most 
reactive HSV-2 patient samples, two and five. To minimize the variability of the sensors in 
response to negative, and potentially positive serum, the electrodes were “pre-blocked” using 
1:10 negative serum, before being challenged with 1:10 HSV-2 positive serum in 3x 
phosphate buffered saline. The FLAG sensor was run in parallel, in identical experimental 
conditions to serve as a negative control in the presence of HSV-2 negative and positive 
serum. Following a one hour of equilibration of the electrodes in positive serum, the sample 
cell was spiked with saturating concentrations of anti-FLAG monoclonal antibody, wherein 
the FLAG sensor served as an internal positive control. These results, found in Figure 20, 
demonstrate no significant signal gain, and therefore differentiation, between positive and 
negative serum by the HSV-2 scaffold sensor. This negative result is further validated by a 
nearly identical signal change by the negative control FLAG sensor in both systems. Upon 
addition of anti-flag monoclonal antibody, the FLAG sensor exhibited a significant signal 
change (~30%) within 15 minutes of addition of anti-FLAG monoclonal antibody (mAb), 
indicating no error in sensor fabrication. Further experimentation, where the gG2 epitope was 
challenged with removed and concentrated antibodies from the most reactive by ELISA 
HSV-2 serum samples, demonstrated no specific binding induced signal gain. When 
challenged with 10x concentrated antibodies in 3x phosphate buffered saline, the signal gain 
by the HSV-2 sensor was mirrored by the FLAG sensor, which was used as control.  
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Figure 20: Electrochemical response of the HSV-2 scaffold sensor over an hour to 1:10 diluted normal serum 
and the most reactive by ELISA HSV-2 seropositive patient samples. Based on the results presented in the 
figure, there was no statistically significant signal gain by the HSV-2 scaffold sensor (right) in response to 
known positive serum samples two (orange) or five (grey) when compared to normal serum (red) and to the 
response of the control FLAG scaffold sensor (left). Sensor batch assembly and functionality success was 
verified by challenging the HSV-2 and FLAG scaffold sensors in 1:10 diluted normal serum spiked with 
saturating concentrations (30 nM) of anti-FLAG monoclonal antibody (black). As seen, the control FLAG 
scaffold sensor underwent a signal gain of 53% (net 40%) over the course of an hour in response to anti-FLAG 
monoclonal antibody, indicating the scaffold sensors were successfully built on the surface. Data points are 
comprised of a three-electrode average and the error bars are the standard error. 
 
 Before declaring the project a failure, additional exploration of the literature produced 
work by Liljeqvist and collaborators79, who demonstrated that the antibody-binding site for 
gG2 epitope actually begins five amino acids residues towards the amino-terminus of the full 
length protein and continued into the first three amino acids of our HSV-2 PNA epitope 
(HRGGPEE). This finding was corroborated by the results of a collaborator, Dr. Michael 
Paull, who screened our collection of HSV-2 positive serum samples against random surface 
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displayed peptide library80. Upon antibody binding to one of the surface displayed peptides, 
the antibody and the bacteria displaying the peptide were removed using protein A/G 
conjugated magnetic beads, which yielded a patient specific antigenic peptide library. 
Immunodominant motifs identified using this method were then compared between HSV-2 
samples, and then compared to the linear amino acid sequence of gG2. Surprisingly, all 
twelve HSV-2 positive patient samples displayed immunogenicity to the sequence 
(GGPEEFEGAGD). When compared to the originally utilized HSV-2 epitope 
(PEEFEGAGDGEPPEDDDS), it becomes clear that if the antibody is binding to our HSV-2 
epitope, greater than half of the epitope is not present. Additionally, if the antibody is binding 
to our PNA, it is binding where it attaches to the DNA/PNA duplex and a long, unbound tail 
of amino acids is free to interact with the components of the serum, which could further 
diminish peptide-antibody binding and increase non-specific binding events and steric 
effects. As a result, a new linear epitope (HRGGPEEFEGAGD) incorporating both 
additional findings was employed for our scaffold sensor platform.  
Despite our expectations, fine-tuning of the immunodominant gG2 linear epitope to 
include the reported antibody binding site did not improve our sensors performance. Initial 
testing by our custom ELISA employing a 1:80 dilution of brand-new patient serum samples, 
yielded high background from the two control sensors employed (FLAG and gp41) with little 
to no statistically significant signal change due to the presence of the anti-gG2 antibody in 
six positive patient serum samples. Furthermore, the negative control (normal serum) 
demonstrated a similarly high signal, which indicates that only three of the six newly 
acquired patient serum samples is can be diagnosed as positive using this epitope by ELISA 
(Figure 21). Despite the less than optimal results from the ELISA, the new HSV-2 scaffold 
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sensor was challenged electrochemically (frequency 60 Hz and amplitude 25 mV) with the 
most reactive by ELISA HSV-2 positive serum samples (patients four and two diluted 1:10 in 
3x phosphate buffered saline). The results, presented in Figure 22, demonstrated no 
statistically significant signal gain when compared to the response from 1:10 diluted normal 
serum in 3x phosphate buffered saline, and the control gp41 scaffold sensor in identical 
experimental conditions. As a last-ditch effort, three of the most reactive of the new HSV-2 
serum samples were pooled, had the antibodies removed via protein G spin trap, and then 
concentrated. When the new HSV-2 scaffold sensor was challenged electrochemically with 
3x phosphate buffered saline containing 10x concentrated antibodies, with the gp41 and 
FLAG sensors in the same solution as controls, the only signal gain observed was due to 
sensor drift and/or the nonspecific adsorption of antibodies, as the signal gain of the HSV-2 
scaffold sensor was mirrored by both controls (Figure 23).  
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Figure 21: Custom PNA scaffold ELISA of the redesigned HSV-2 immunodominant epitope against newly 
purchased HSV-2 seropositive and seronegative patient samples. As illustrated by the figure, three out of six 
serum samples were identified as positive using this linear immunodominant epitope, with the remaining three 
serum samples providing a signal that was less than, or within one standard deviation of the negative controls, 
either HIV negative serum pool or normal serum. HCV seropositive patient sample 1 was included in this 
experiment in the hopes of identifying a dual disease state patient sample. The signal of this sample is so close 
to the normal serum sample, determination of dual infection modalities is inconclusive from this data. Here, the 
FLAG (black) and gp41 (orange) PNA were used as a control, demonstrating abnormally high signal in 
response to all serum (save HIV negative). Subsequent optimization and blocking conditions, washing, and 
optimization of secondary antibody concentration still showed high background signal from FLAG and gp41 
PNA controls. Data points are comprised of a three well average and the error bars represent the standard error. 
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Figure 22: Electrochemical response of the redesigned HSV-2 scaffold sensor over an hour to 1:10 diluted 
normal serum and the most reactive by ELISA HSV-2 seropositive patient samples. Based on the results 
presented in the figure, there was no diagnostically significant signal gain by the HSV-2 scaffold sensor (left) in 
response to known positive serum samples four (orange) or two (black) when compared normal serum (red) and 
the control gp41 scaffold sensor (right). Data points are comprised of a three-electrode average and the error 
bars are the standard error. 
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Figure 23: Redesigned HSV-2 scaffold sensor challenged with antibodies removed and concentrated from the 
three most reactive HSV-2 seropositive patients by ELISA (patients 1,2 and 5). Antibodies were removed using 
a protein G spin trap and concentrated using size exclusion protein concentrators. Removed and concentrated 
antibodies from the HSV-2 serum were spiked into 3x phosphate buffer to a final concentration of ten times 
their concentration in 100% serum. As demonstrated by the figure, there is no statistically significant signal gain 
by the HSV-2 scaffold sensor (red) in the presence of removed and concentrated antibodies in buffer, as 
evidenced by nearly identical signal gain by the FLAG (orange) and gp41 (black) scaffold sensors, which was 
used as a control.  Data points are comprised of an average and the error bars are the standard error (n=3). 
 
3.5 Discussion about the expansion of multiple biomarkers and general trends observed 
 Overall, successful expansion of our E-DNA scaffold sensing platform to include 
linear epitopes diagnostically relevant for additional diseases has remained elusive. Save for 
the initial success with the anti-gp41 linear epitope17,40, the results above demonstrate the 
difficulty of integrating linear epitopes for HCV and HSV-2 into our platform (Figures 16-
23). The most pressing problem is the result of a limited understanding of our E-DNA 
scaffold sensor chemistry: a diagnostic synthetic peptide from literature that demonstrates a 
high binding affinity by commercial and custom scaffold sensor ELISA subsequently fails 
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when challenged with positive human serum on the electrode surface. Through this work, a 
set of experiments has been identified to quickly eliminate a linear epitope as unsuitable for 
the E-DNA scaffold sensing platform. A plethora of other linear epitopes, for multiple 
diseases, including but not limited to STIs, exist and can be successfully integrated into our 
E-DNA scaffold sensor for diagnosis.  
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Chapter 4: Conclusions  
 In response to the need for quantitative point of care serology we have developed a 
reagentless, electrochemical platform for the measurement of specific antibodies in complex 
clinical samples17,31,81. These consist of a short, relatively rigid nucleic acid duplex scaffold 
anchored at one end to a gold electrode via a flexible linker and modified on their other end 
with a redox reporter and an antibody-binding epitope. In the absence of the target antibody, 
the flexibility of the linker allows the reporter to approach the electrode surface, producing a 
large faradaic current when the electrode is interrogated using square wave voltammetry. The 
binding of an antibody to the epitope decreases the efficiency of this approach, producing an 
easily measured reduction in current. The resulting output linearly relates to the fraction of 
the epitope molecules bound, and thus the platform is, like ELISAs, quantitative. And 
because it is supported on micron-scale electrodes, it is likewise easily multiplexed36. 
Moreover, in being rapid (<15 min), single-step, and selective enough to work in blood 
serum, the platform also encompasses many of the promising attributes that have allowed 
LIAs and agglutination assays to penetrate at the point of care.  
One of the first goals of this work was to improve on the raw current and signal gain 
of the previously published E-DNA scaffold sensor. Several modifications of the base pair 
complementarity and the resulting flexibility of the scaffold were investigated in the hopes of 
raising the raw current above the nanoamp regime and to increasing the binding-induced 
signal change. Based on experimental evidence, the three variations of the traditional scaffold 
sensor architecture explored here did not appreciably improve the raw current of the scaffold 
sensor. These same constructs demonstrated significantly diminished binding induced signal 
change in the presence of target antibody. Based on these results, it appears that original the 
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rigid scaffold with complete complementarity is the best choice for our E-DNA scaffold 
sensor architecture.  
The inclusion of a secondary linear epitope to create a bivalent epitope sensor, which 
would increase the binding affinity and limit of detection, was similarly unsuccessful, 
underperforming the traditional monovalent E-DNA scaffold sensor at high and low specific 
antibody concentrations, for all frequency and amplitude combinations. However, this idea 
still has significant merit for improving the E-DNA scaffold sensor. This research only 
evaluated the performance of one bivalent epitope architecture, where the first linear epitope 
was twelve base pairs away from the electrode surface and directly underneath the second 
epitope. Utilization of “Y” shaped architecture where the epitopes are displayed distally, 
which mimics the shape of antibodies, increasing the distance of the first epitope from the 
electrode surface, or introducing a binding induced change in position of the redox reporter 
upon binding of the second epitope may yield success in creating a bivalent epitope sensor. 
The second goal of this work was to expand the number of diagnostically relevant 
antibodies detected by the E-DNA scaffold sensor platform. To date, only the anti-gp41 E-
DNA scaffold sensor has the potential to be utilized as a point of care diagnostic device. 
Incorporation of linear immunodominant epitopes from HCV and HSV-2 have thus far been 
unsuccessful. Based on experience, lack of successful integration into the E-DNA scaffold 
sensor stems from the following: 1) limitations in the available literature and commercial 
products, and 2) understanding how ELISA results inform on the success of E-DNA scaffold 
sensing. 
 Most of the literature available on the linear epitopes against diagnostically 
significant antibodies was done in the late 1980s and early 1990s. Initially, scientists 
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extensively studied and characterized linear immunodominant epitopes for diagnosis because 
they were cheaper and easier to produce than recombinant full-length antigens. With 
improvements in microfluidics, molecular imaging, protein purification and inexpensive 
expression vectors, serology has moved towards using full length antigens for diagnosis. 
Because of this, explorations of the literature to identifying linear, immunodominant epitopes 
usually have no follow up use/experimentation, and it is unclear if this is because other 
researchers did not experience the same success using the linear epitope, or if because use of 
this linear epitope simply became obsolete. Furthermore, identifying commercially available 
antibodies for use as a positive control and to determine the limit of detection is nearly 
impossible because characterizations of an antibody’s epitope is unnecessary when using the 
full-length antigen for diagnosis. While one could order several different antibodies under the 
assumption that one of them should bind a least a portion of your linear epitope (under the 
assumption that, because it is immunodominant in humans, it is likely immunodominant in 
the organism from which the monoclonals were derived), blindly “throwing” antibodies at 
your linear epitope to find a good positive control is a rather expensive approach. 
 As we saw for the HCV scaffold sensor, and less so for HSV-2 scaffold sensor, a high 
signal as the result of seropositive serum in ELISA does not mean that the scaffold sensor 
will achieve similar results. As seen in this work, a high optical density signal in ELISA 
using the scaffold sensor architecture resulted in no diagnostically significant signal change 
electrochemically. Further work to understand this relationship, so we are better able to 
predict the success of incorporation of these linear epitopes into our scaffold sensors would 
improve experimental outcomes. Additionally, development of a high throughput method 
which screens multiple peptides to determine if they are immunodominant and can be 
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incorporated successfully into our scaffold sensing platform would be of benefit, both by 
reducing cost (PNAs are in the thousands of dollars) and time (PNAs take approximately 3 
months to synthesize). While this was briefly explored using synthetic biotin-conjugated 
FLAG peptides (work not included here), these synthetic peptides were almost as expensive 
as PNAs and my attempts were unsuccessful.  
The future of E-DNA scaffold sensors, along with the rest of diagnostic serology, is 
moving in the direction of using full-length or truncated antigen. Use of these biomolecules 
has the added benefit of presenting all (or most) of linear and conformational epitopes. Work 
by others in the Plaxco group have successfully demonstrated definitive diagnosis within the 
point of care window using scaffold sensors architectures incorporating larger antigenic 
fragments. To date, there has been successful detection of syphilis using truncated TPN17 
and early detection of HIV-1/2 using a p24 monobody. However, until long term stability of 
proteins on an electrode surface can be achieved and explorations of scaffold sensor design 
result in diagnostically significant signal gain upon antibody binding independent of antigen 
size, the use of linear epitopes is still the best bet for overcoming the current limitations in 
point of care diagnostics with electrochemistry.  
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Chapter 5: Experimental 
5.1 Materials 
Anti-FLAG monoclonal antibody produced in mouse, anti-digoxigenin monoclonal 
antibody produced in mouse, 6-mercaptohexanol, sulfuric acid, bovine serum albumin, anti-
human (Fc specific) IgG–peroxidase antibodies, anti-mouse (Fc specific) IgG –peroxidase 
antibodies 3,3’,5,5’-Tetramethylbenzidine (TMB) and Tween-20 were purchased from 
Sigma-Aldrich (Saint Louis, MO). Clear 96 well streptavidin coated plates with bovine 
serum albumin blocker, human plasma fibrinogen, glycine-HCL, sodium phosphate 
monobasic monohydrate, sodium phosphate dibasic monohydrate, sodium hydroxide, tris (2-
cholorethyl) phosphate (TCEP), UltraPure distilled water, and potassium chloride were 
purchased from Fisher Scientific (Saint Louis, MO). Protein G HP Spin Trap obtained from 
VWR International (San Francisco, CA). Amicon ultra-15 centrifugal units were obtained 
from Millipore Sigma (Burlington, MA). All above materials were used as received. 
Human HCV positive serum samples and human serum negative for HIV, HSV-1, 
HSV-2, HAV, HBV, HCV, and syphilis, identified in work as “negative serum”, was 
obtained from Biorelamation IVT (Hicksville, NY).  Human HIV negative and positive 
serum samples for HIV types one and two were obtained from Diagnostic Biosamples (San 
Diego, CA). Human HSV-2 positive serum samples were obtained from Discovery Life 
Sciences (Los Osos, CA). 
HPLC purified and lyophilized custom oligonucleotide DNA sequences with distal 
covalently attached variable redox reporter and terminal sulfur or biotin modifications were 
ordered from Biosearch Technologies (Novato, CA). HPLC purified custom oligonucleotides 
with a covalently attached variably positioned digoxigenin was obtained from Fidelity Oligos 
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(Gaithersburg, MD).  All DNA stock solutions were diluted to approximately 100 µM using 
UltraPure distilled water and stored at -20°C in the original packaging. Peptide nucleic acid 
epitope chimeras were obtained from PNA Bio (Thousand Oaks, CA). All PNA stock 
solutions were diluted to 50.1 µM using UltraPure Distilled water and stored at -20 °C in the 
original packaging. 
Platinum wire counter electrodes, aqueous Ag/AgCl reference electrodes, 2 mm 
diameter gold working electrodes were obtained from CH instruments (Bee Cave, TX). 
Platinum wire counter electrodes and 2mm diameter gold electrodes were used as received. 
Ag/AgCl reference electrodes were submerged in 3 mM KCl within the inner housing of the 
electrode before use.   
5.2 Instrumentation 
All electrochemical measurements were performed on a 1000C series multi-channel 
potentiostat from CH instruments (Bee Cave, TX). Enzyme linked immunosorbent assays 
were spectrophotometrically analyzed using a Tecan Infinite 200 PRO from Tecan 
(Mannedorf, Switzerland). Centrifugation was performed using a 5427 Centrifuge from 
Eppendorf (Hamburg, Germany). All deionized (DI) water used in methods was further 
purified by going through a Milli-Q Integral Water Purification System from MiliporeSigma 
(Burlington, MA). 
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5.3 DNA and PNA sequences 
All DNA Sequences are written from the 5’ to the 3’ end. 
DNA anchor strand used in electrochemical measurements where nucleic acids are 
capitalized:  
(27mer): S-(CH2)6-GCA GTA ACA AGA ATA AAA CGC CAC TGC-Methylene 
Blue 
DNA anchor stranded used in ELISA: 
(27mer): Biotin-GCA GTA ACA AGA ATA AAA CGC CAC TGC 
DNA complement strands used in investigation of scaffold flexibility:  
Sequence 1 (Dig 1):  
Digoxigenin -(CH2)6-GCA-GTG-GCG-TTT-TAT-TCT-TGT-TAC-TGC 
Sequence 2 (Dig 2):  
Digoxigenin-(CH2)6 -GCA-GTG-GCG-TCC-CGC-CCT-TGT-TAC-TGC 
Sequence 3 (Dig 3):  
Digoxigenin -(CH2)6-GCA-GTG-ATA-TTT-TAT-CTC-TGT-TAC-TGC 
Sequence 4 (Dig 4):  
Digoxigenin -(CH2)6-GCG-TTT-TAT-TCT 
All PNA are written from the N-terminus end, where amino acids are capitalized and peptide 
nucleic acids are lower case: 
FLAG: DYKDDDDKGG-cag tgg cgt ttt att ctt gtt act g 
HIV gp41: CSGKLICTTAVPW-cag tgg cgt ttt att ctt gtt act g  
HSV-2 OLD: PEEFEGAGDGEPPEDDDS-(C-S)-cagtggcgttttattcttgttactg 
HSV-2 NEW: HRGGPEEFEGAGD-cag tgg cgt ttt att ctt gtt act g 
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HCV: MSTNPKPQKKNKRNTNRRPQDVKFPGGG – catggcgttttattcttgttactg 
 
5.4 Methods 
5.4.1 Enzyme linked immunosorbent assay 
A customized ELISA was developed in our lab to utilize the same PNA-epitope 
chimera used in our E-DNA scaffold sensors. First, the 96 well streptavidin coated plate was 
washed three times with the ELISA washing buffer (1x phosphate buffered saline, 0.05% 
tween-20, 2% bovine serum albumin adjusted to pH 7.6 using 1 M sodium hydroxide). Next, 
100 µL of biotin conjugated DNA anchor diluted in phosphate buffered saline (pH 7.6) at a 
concentration of 60 nM was placed into each of the wells and incubated for two hours . The 
plate was then washed three times with washing buffer before each well was incubated with 
100 µL of 200 nM PNA diluted in phosphate buffered saline (pH 7.6) for one hour. The plate 
was then washed three times with the washing buffer before 100 µL of variable dilutions 
(1:1000 to 1:10 dilution) of human serum in washing buffer were placed in the wells (per 
experimental design) and allowed to incubate for one hour. Following an additional six 
washes with washing buffer, 100 µL of 1:15000 diluted peroxidase conjugated secondary 
antibody (either anti-human or anti-mouse, per experimental design) in washing buffer was 
placed into each of the wells for an incubation of thirty minutes. The plate was again washed 
five times before each well was incubated with 100 µL of TMB substrate. Color from the 
peroxidase-TMB reaction was allowed to develop before the reaction was stopped with 50 
µL of 2 M sulfuric acid. Results were evaluated by averaging the absorption of each well at 
450 nm for 25 flashes of light using the Tecan Microplate reader. 
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All experiments were repeated triplicate using separate wells. ELISA data presented 
figures is the average of those three wells and with error bars representing one standard 
deviation. 
5.4.2 Electrochemical Measurements 
Prior to building the E-DNA scaffold on the surface, the 2 mm diameter gold 
electrodes were mechanically polished using a 0.05 µm aluminum oxide slurry. The 
electrodes were then electrochemically cleaned in the following steps: 1) a reductive 
desorption of any organic contaminants using cyclic voltammetry in 0.5 M sodium 
hydroxide, 3) potential cycling in 0.5 M sulfuric acid using cyclic voltammetry to further 
remove organic contaminants while forming and reducing a gold oxide layer, 3) chloride 
etching to further clean the gold surface using 0.1 M sulfuric acid and 0.01 M potassium 
chloride, and 4) complete reduction of the gold surface in 0.05 M sulfuric acid using cyclic 
voltammetry. The electrodes are then rinsed with DI water before building the scaffold 
sensor on the clean, reduced gold surface. 
Following mechanical and electrochemical cleaning, the electrodes are placed in 100 
µL of variable concentrations of the DNA anchor solution (per experimental design) with a 
terminal thiol that has been reduced over the course of an hour to prevent any disulfide bonds 
TCEP (10 mM in DI water). After incubating with the DNA anchor for one hour at room 
temperature (~25 °C), electrode was placed into 100 µL of 5 mM 6-mercaptohexanol in DI 
water where it was incubated overnight (12-16 hours) at 4 °C. The next day electrodes were 
placed in 100 µL of the requisite PNA with a concentration of at least four times the 
concentration of anchor strand and incubated for two hours. 
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Working electrodes with the scaffold sensor and SAM on the surface, the platinum 
counter electrode, and the Ag/AgCl reference electrode were then connected to the 
potentiostat. These electrodes were submerged in a blocking solution (3x phosphate buffered 
saline, 0.05% tween-20, and 1% fibrinogen) and allowed to equilibrate for 20 minutes. 
Following this equilibration step, electrodes were then challenged with variable dilutions 
(1:1000 to 1:10 dilution) of patient serum or monoclonal antibody by direct addition into the 
blocking solution, depending on experimental design. Alternatively, electrodes were blocked 
with the above-mentioned blocking solution, before additional blocking using variable 
dilutions (1:40 to 1:10) of known negative human serum before being challenged with dilute 
positive serum or monoclonal antibody. All experiments were performed square wave 
voltammetry (approximately one scan/minute) with a frequency of 60 Hz and an amplitude 
of 0.25 mV between -0.05 and -0.45, which is the potential window for the reduction of 
methylene blue relative to the Ag/AgCl reference. 
Frequency-amplitude tuning was performed using continuous scanning (variable time 
between scans on each based on frequency) by square wave voltammetry in 3x phosphate 
buffered saline (pH 7.6) at a range of 1-500 Hz and 10-100 mV, respectively. After cycling 
through designated frequency amplitude pairs within the above ranges, the electrodes were 
again scanned under the same square wave voltammetry conditions after 30 minutes of 
equilibration with target serum (1:10 dilution) or monoclonal antibody at saturating 
concentrations. 
All experiments were repeated triplicate using separate electrodes. Electrochemical 
data presented figures is the average of those three electrodes and with error bars 
representing one standard deviation. 
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5.4.3 Data Analysis 
Electrochemical data: 
 Data collected from the electrochemical experiments conducted on the CH 
instruments multichannel potentiostat were analyzed using MatLab (Natick, MA). In brief, 
data from electrochemical experiments was converted into a test file that was accessed by 
MatLab. At MatLab script was then applied to the data file, which created a flat baseline by 
connecting points on either side of the reduction peak as designated by the user (typically 
between approximately -0.15 and -0.35 V). The program then determined the maximum 
current within the given interval and subtracted the baseline current, which yields the current 
for that electrode. This data was then imported into Microsoft Excel (Redmond, WA), where 
change in current as a function of time after exposure to either blocking conditions or 
positive or negative serum was determined. The percent change in was current was 
determined by performed by subtracting the starting current (before challenge) with the 
current challenge, diving by the starting current, and then multiplying by 100. Electrode 
changes in signal for triplicate measurements were then averaged and the standard deviation 
was determined. 
 
ELISA Data: 
Data collected via the Tecan multiplate reader was analyzed using Microsoft Excel. 
The triplicate experimental conditions were averaged, and the standard deviation was 
calculated. 
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